Neuropathic Ocular Pain Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Novartis, OKYO Pharma, AbbVie Inc., Aciex Therapeutics, Novaliq, Oculeve and Allergan, Adverum Biotechnologies

DelveInsight's "Neuropathic Ocular Pain Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Neuropathic Ocular Pain, historical and forecasted epidemiology as well as the Neuropathic Ocular Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Neuropathic Ocular Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neuropathic Ocular Pain Market Forecast
https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Neuropathic Ocular Pain Market Report:
• The Neuropathic Ocular Pain market size is anticipated to grow with a significant CAGR of 5.2% during the study period (2020-2034)
• In February 2024, OKYO Pharma obtained FDA approval for an Investigational New Drug (IND) application for OK-101, making it the first drug authorized to target neuropathic corneal pain (NCP), which has considerable unmet needs. Classified as an orphan disease, this approval underscores OK-101's potential to address both NCP and neuropathic ocular pain (NOP), for which there is currently no FDA-approved treatment.
• In 2023, the total number of Neuropathic Ocular Pain (NOP) cases across various eye disorders and surgeries was estimated to be around 3,075 thousand in the 7MM, with expectations for this figure to rise by 2034.
• In 2023, the Neuropathic Ocular Pain (NOP) market consists of off-label therapies that provide only temporary and nonspecific relief, leading to an estimated market size of around USD 100 million across the 7MM.
• In DelveInsight's evaluation, Japan reported a total of 3,352 thousand cases of various eye disorders in 2023. Among these, severe Dry Eye Disease accounted for 36%, post-operative complications made up 13%, cataract surgery represented 29%, and other conditions, including infections, systemic diseases, and various ocular surface disorders, constituted 21%.
• In 2023, the EU4 and the UK represented about 1,625 thousand cases of neuropathic ocular pain within the 7MM. Among the European nations, Italy reported the highest incidence, with approximately 535 thousand cases, while France followed with nearly 350 thousand cases.
• According to DelveInsight's projections for 2023, the EU4 and the UK represent 44% of the total cases of various eye disorders and surgeries across the 7MM, exceeding the US at 38% and Japan at 18%. These figures are anticipated to increase during the forecast period from 2024 to 2034, signaling a projected rise in the prevalence of these conditions.
• Key Neuropathic Ocular Pain Companies: Novartis, OKYO Pharma, AbbVie Inc., Aciex Therapeutics, Novaliq, Oculeve and Allergan, Adverum Biotechnologies, MeiraGTx, Ocular Therapeutix, Aldeyra Therapeutics, IACTA Pharmaceuticals, Inc., Sun Pharmaceutical Ltd., SALVAT, Bausch & Lomb Incorporated, Kala Pharmaceuticals, Spectra Vision Care., Alcon Laboratories, AERIE PHARMACEUTICALS, INC., Optocred Pharmaceuticals, BRIM Biotechnology, Inc., and others
• Key Neuropathic Ocular Pain Therapies: SAF312, OK-201, Lidocaine, Ketamine, Nerve stimulation, Gene Therapy, Gabapentin, Pregabalin, and others
• The Neuropathic Ocular Pain epidemiology based on gender analyzed that Neuropathic Ocular Pain (NOP) affects males and female equally
• The Neuropathic Ocular Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neuropathic Ocular Pain pipeline products will significantly revolutionize the Neuropathic Ocular Pain market dynamics.

Neuropathic Ocular Pain Overview
Neuropathic ocular pain (NOP), also referred to as corneal neuropathic pain, is a condition in which corneal pain is seen in response to normally non-painful stimuli. This pain results from repeated direct damage to corneal nerves.

Get a Free sample for the Neuropathic Ocular Pain Market Report -
https://www.delveinsight.com/report-store/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Neuropathic Ocular Pain Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Neuropathic Ocular Pain Epidemiology Segmentation:
The Neuropathic Ocular Pain market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Neuropathic Ocular Pain
• Prevalent Cases of Neuropathic Ocular Pain by severity
• Gender-specific Prevalence of Neuropathic Ocular Pain
• Diagnosed Cases of Episodic and Chronic Neuropathic Ocular Pain

Download the report to understand which factors are driving Neuropathic Ocular Pain epidemiology trends @ Neuropathic Ocular Pain Epidemiology Forecast
https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Neuropathic Ocular Pain Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neuropathic Ocular Pain market or expected to get launched during the study period. The analysis covers Neuropathic Ocular Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Neuropathic Ocular Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Neuropathic Ocular Pain Therapies and Key Companies
• SAF312: Novartis
• OK-201: OKYO Pharma
• Lidocaine: Aciex Therapeutics
• Ketamine: Novaliq
• Nerve stimulation: Oculeve and Allergan
• Gene Therapy: Adverum Biotechnologies and MeiraGTx
• Gabapentin: Ocular Therapeutix
• Pregabalin: Aldeyra Therapeutics

Discover more about therapies set to grab major Neuropathic Ocular Pain market share @ Neuropathic Ocular Pain Treatment Market
https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Neuropathic Ocular Pain Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Neuropathic Ocular Pain Companies: Novartis, OKYO Pharma, AbbVie Inc., Aciex Therapeutics, Novaliq, Oculeve and Allergan, Adverum Biotechnologies, MeiraGTx, Ocular Therapeutix, Aldeyra Therapeutics, IACTA Pharmaceuticals, Inc., Sun Pharmaceutical Ltd., SALVAT, Bausch & Lomb Incorporated, Kala Pharmaceuticals, Spectra Vision Care., Alcon Laboratories, AERIE PHARMACEUTICALS, INC., Optocred Pharmaceuticals, BRIM Biotechnology, Inc., and others
• Key Neuropathic Ocular Pain Therapies: SAF312, OK-201, Lidocaine, Ketamine, Nerve stimulation, Gene Therapy, Gabapentin, Pregabalin, and others
• Neuropathic Ocular Pain Therapeutic Assessment: Neuropathic Ocular Pain current marketed and Neuropathic Ocular Pain emerging therapies
• Neuropathic Ocular Pain Market Dynamics: Neuropathic Ocular Pain market drivers and Neuropathic Ocular Pain market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Neuropathic Ocular Pain Unmet Needs, KOL's views, Analyst's views, Neuropathic Ocular Pain Market Access and Reimbursement

To know more about Neuropathic Ocular Pain companies working in the treatment market, visit @ Neuropathic Ocular Pain Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Neuropathic Ocular Pain Market Report Introduction
2. Executive Summary for Neuropathic Ocular Pain
3. SWOT analysis of Neuropathic Ocular Pain
4. Neuropathic Ocular Pain Patient Share (%) Overview at a Glance
5. Neuropathic Ocular Pain Market Overview at a Glance
6. Neuropathic Ocular Pain Disease Background and Overview
7. Neuropathic Ocular Pain Epidemiology and Patient Population
8. Country-Specific Patient Population of Neuropathic Ocular Pain
9. Neuropathic Ocular Pain Current Treatment and Medical Practices
10. Neuropathic Ocular Pain Unmet Needs
11. Neuropathic Ocular Pain Emerging Therapies
12. Neuropathic Ocular Pain Market Outlook
13. Country-Wise Neuropathic Ocular Pain Market Analysis (2020-2034)
14. Neuropathic Ocular Pain Market Access and Reimbursement of Therapies
15. Neuropathic Ocular Pain Market Drivers
16. Neuropathic Ocular Pain Market Barriers
17. Neuropathic Ocular Pain Appendix
18. Neuropathic Ocular Pain Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Neuropathic Ocular Pain Epidemiology https://www.delveinsight.com/report-store/neuropathic-ocular-pain-nop-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Neuropathic Ocular Pain Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Neuropathic Ocular Pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Microscopy Device Market: https://www.delveinsight.com/report-store/microscopy-device-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Percutaneous Arterial Closure Device Market: https://www.delveinsight.com/report-store/vascular-closure-devices-market
• Transdermal Drug Delivery Devices: https://www.delveinsight.com/report-store/transdermal-drug-delivery-devices-market
• Infusion Pumps Market: https://www.delveinsight.com/report-store/infusion-pumps-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.